2nd Oligonucleotide-Based Therapeutics Summit

Maximizing the Affinity, Specificity, and Efficacy of Oligonucleotide Therapeutics through Smarter Chemistry and Tissue- and Cell-Specific Delivery to Translate Innovation into Clinical Success

URLs:
Website: https://go.evvnt.com/3812341-0?pid=2874
Brochure: https://go.evvnt.com/3812341-3?pid=2874

Category: Conferences

Prices:
Primary Pricing - Conference + Workshop Day: USD 4397.00,
Primary Pricing - Conference Only: USD 3099.00,
Discounted Pricing - Conference + Workshop Day: USD 3797.00,
Discounted Pricing - Conference Only: USD 2699.00,
Vendor Pricing - Conference + Workshop Day: USD 5297.00,
Vendor Pricing - Conference Only: USD 3799.00

Speakers: Sudhir Agrawal, Founder and President, ARNAY Sciences, Jacek Ostrowski, Senior Director - Protein Science, Avidity Biosciences, Inc., Jiabao Zhang, Senior Scientist, Biogen, Daniel Tardiff, Chief Scientific Officer, CAMP4 Therapeutics, Seymour de Picciotto, CEO, Cellado, Paul Peng, Vice President - CMC, City Therapeutics, Manuel Mohr, Co-Founder and Chief Executive Officer, D2B3, Inc., Stephanie Maiocco, VP of Biotherapeutics, Evercrisp, Alfica Sehgal, Chief Scientific Officer, Judo Bio, Sayantan Chatterjee, Oligonucleotide Chemistry Scientist, Korro Bio, Qian Chen, Founder - Scientific, NanoDe Therapeutics, Rowshon Alam, Vice President, Head of Process Chemistry and In-process Analytics, Prime Medicine, Steve Dowdy, Professor, University of California, San Francisco, Ken Yamada, Assistant Professor, University of Massachusetts Medical School, Thomas Ormsby, Associate Professor, University of Massachusetts Medical School, Julia Alterman, Assistant professor, University of Massachusetts Medical School, Cecilia Leung, VP of Research, Vivatides Therapeutics, Shuhan Huang, Scientist, WYSS